The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes

Diabetes

Volumn 51, Issue 9, 2002, Pages 2826-2832

  Stitt, Alan ^a,c   Gardiner, Thomas A ^a   Anderson, Nathan L ^b   Canning, Paul ^a   Frizzell, Norma ^a   Duffy, Noel ^a   Boyle, Cliona ^a   Januszewski, Andrzej S ^b   Chachich, Mark ^b   Baynes, John W ^b   Thorpe, Suzanne R ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; ANTIOXIDANT; LAMININ; LIPID; LIPOXIDATION END PRODUCT; MESSENGER RNA; PYRIDOXAMINE; STREPTOZOCIN; THIOCTIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; MICROVASCULATURE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; RETINA BLOOD VESSEL OCCLUSION; VASCULAR LESION;

EID: 0036723821     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.9.2826     Document Type: Article

References (53)

1. Early cellular and molecular changes induced by diabetes in the retina
2. Advanced glycation: An important pathological event in diabetic and age related ocular disease
3. Glycoxidation and lipoxidation in atherogenesis
4. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose
5. N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins
6. Mechanism of autoxidative glycosylation: Identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose
7. Pharmacological modulation of AGEs: A unique role for redox-active metal ions
8. Glycochelates and the etiology of diabetic peripheral neuropathy
9. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
10. Advanced glyeation alters expression of the 67kDa laminin receptor in capillary endothelial cells: Implications for diabetic microangiopathy
11. Toxic action of advanced glyeation end products on cultured retinal capillary pericytes and endothelial cells: Relevance to diabetic retinopathy
12. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products
13. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy
14. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats
15. Advanced glycation end products induce blood-retinal barrier dysfunction in normo-glycemic rats
16. Response of capillary cell death to aminoguanidine predicts the development of retinopathy: Comparison of diabetes and galactosemia
17. Effects of inhibition of glycation and oxidative stress on the development of cataract and retinal vessel abnormalities in diabetic rats
18. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy
19. Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model
20. Pharmacological inhibition of diabetic retinopathy: Aminoguanidine and aspirin
21. Aminoguanidine inhibits oxidative modification of low-density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors
22. Anmoguanidine has both pro-oxidant and antioxidant activity toward LDL
23. Oxidative retinal products and ocular damages in diabetic patients
24. Serum markers of oxidative stress and severity of diabetic retinopathy
25. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. IV. Antioxidant defense system
26. The role of oxidative stress in diabetic retinopathy
27. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes
28. Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term admnistration of antioxidants on the development of retinopathy
29. Early changes in lipid peroxidation and antioxidative defense in diabetic rat retina: Effect of DL-alpha-lipoic acid
30. Retinal vascular changes induced by the oxidative stress of alpha-tocopherol deficiency contrasted with diabetic microangiopathy
31. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat
32. Amadorins: Novel post-Amadori inhibitors of advanced glycation reactions
33. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions: Mechanism of action of pyridoxamine
34. Chemistry and metabolism of lipids in the vertebrate retina
35. Qunatification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoproteins
36. ε-(carboxy-methyl)lysine is a dominant advanced glycation end-product (AGE) antigen in tissue proteins
37. Expression of the VEGF gene family during retinal vaso-obliteration and hypoxia
38. Retinal VEGF mRNA measured by SYBR green I fluorescence: A versatile approach to quantitative PCR
39. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs): Novel inhibition of post-Amadori glycation pathways
40. A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation
41. Advanced glycation endproducts accelerate calcification in microvascular pericytes
42. Growth modulation of retinal microvascular cells by early and advanced glycation products
43. Basement membrane and growth factor gene expression in normal and diabetic human retinas
44. Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats
45. Early biosynthetic changes in the diabetic4ike retinopathy of galactose-fed rats
46. Alterations in human glomerular epithelial cells interacting with nonenzymatically glycosylated matrix
47. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen
48. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease
49. The effect of advanced glycation end-product formation upon cell-matrix interactions
50. Diabetes-induced changes in retinal NAD-redox status: Pharmacological modulation and implications for pathogenesis of diabetic retinopathy
51. Antioxidant treatment of experimental diabetic retinopathy in rats with nicanartine
52. Role of dyslipidemia and AGE/ALE formation in the progression of nephropathy and retinopathy in STZ-diabetic rats
53. ε-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions